Rhes suppression enhances disease phenotypes in Huntington's disease mice

  • Lee J
  • Sowada M
  • Boudreau R
 et al. 
  • 29


    Mendeley users who have this article in their library.
  • 5


    Citations of this article.


In Huntington's disease (HD) mutant HTT is ubiquitously expressed yet the striatum undergoes profound early degeneration. Cell culture studies suggest that a striatal-enriched protein, Rhes, may account for this vulnerability. We investigated the therapeutic potential of silencing Rhes in vivo using inhibitory RNAs (miRhes). While Rhes suppression was tolerated in wildtype mice, it failed to improve rotarod function in two distinct HD mouse models. Additionally, miRhes treated HD mice had increased anxiety-like behaviors and enhanced striatal atrophy as measured by longitudinal MRI when compared to control treated mice. These findings raise caution regarding the long-term implementation of inhibiting Rhes as a therapy for HD.

Author-supplied keywords

  • Huntington disease
  • RNA interference
  • Rhes
  • genetic therapies
  • neurodegenerative disease
  • rasd2

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • John H. Lee

  • Matthew J. Sowada

  • Ryan L. Boudreau

  • Andrea M. Aerts

  • Daniel R. Thedens

  • Peg Nopoulos

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free